INKT
Mink Therapeutics Inc
NASDAQ: INKT · HEALTHCARE · BIOTECHNOLOGY
$10.80
+1.60% today
Updated 2026-10-28
Market cap
$51.34M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.39
Dividend yield
—
52W range
$8 – $17
Volume
0.0M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C3.8
Quality
D3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-18.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$42.50
+293.52%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -18.23 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.08M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $2.70B | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-27.99M | $-22.46M | $-10.78M | $-12.49M | $-3.13M |
| EPS | — | — | — | — | $-2.39 |
| Free cash flow | $-19.12M | $-15.84M | $-9.56M | $-5.93M | $-2.08M |
| Profit margin | -1.03% | — | — | — | — |
Peer comparison
Smart narrative
Mink Therapeutics Inc trades at $10.80. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -18.23, it sits in the distress.
Frequently asked questions
What is Mink Therapeutics Inc's stock price?
Mink Therapeutics Inc (INKT) trades at $10.80.
Is Mink Therapeutics Inc overvalued?
Mink Therapeutics Inc carries a Smart Value Score of 16/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Mink Therapeutics Inc (INKT)?
The 12-month analyst consensus target is $42.50, about 293.5% above the current $10.80. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Mink Therapeutics Inc's Altman Z-Score is -18.23, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-1,239.00%
Beta0.47
50D MA$11.44
200D MA$11.34
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—